Day: June 3, 2020

– High Variability in Levels of Biomarkers in Control Arm of Phase 2b Study May Drive Reassessment of Overall Study Results –– Effects Of PTI-125 on Cognition, Other Analysis and Data Expected 2nd Half 2020 –– Updated Corporate Presentation Now Available on Website –AUSTIN, Texas, June 03, 2020 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq:SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that management is scheduled to present at the Jefferies Virtual Healthcare Conference today, June 3, 2020, at 3:00 pm EST.Cassava Sciences also provided an update, including a discussion regarding recently announced top-line results of a Phase 2b randomized, placebo-controlled study of PTI-125 in patients with Alzheimer’s disease. The Company believes high variability...

Pursuant to section 30 of the Danish Capital Market Act it is hereby announced that Kapitalforeningen Investering & Tryghed, in accordance with section 38,1 of the Danish Capital Market Act, has informed Gabriel Holding A/S that Kapitalforeningen Investering & Tryghed on 2 June 2020 has purchased 50.000 shares in Gabriel Holding A/S, corresponding to 2.65% of the share capital and voting rights in Gabriel Holding A/S.Following the purchase of shares in Gabriel Holding A/S, Kapitalforeningen Investering & Tryghed now holds 117,295 shares corresponding to 6.21% of the share capital and voting rights in Gabriel Holding A/S.

Med henvisning til Kapitalmarkedslovens § 30 oplyses det hermed, at Kapitalforeningen Investering & Tryghed i henhold til Kapitalmarkedslovens § 38, stk. 1, har meddelt Gabriel Holding A/S, at Kapitalforeningen Investering & Tryghed d. 2. juni 2020 har købt 50.000 stk. aktier i Gabriel Holding A/S svarende til 2,65 % af aktiekapitalen og stemmerne i Gabriel Holding A/S.Efter købet af aktierne i Gabriel Holding A/S, har Kapitalforeningen Investering & Tryghed en beholdning på i alt 117.295 aktier svarende til 6,21% af aktiekapitalen og stemmerne i Gabriel Holding A/S.Vedhæftet filGabriel Holding AS – Meddelelse nr. 9 – Storaktionær

Pursuant to section 30 of the Danish Capital Market Act it is hereby announced that GAB Invest ApS in accordance with section 38,1 of the Danish Capital Market Act has informed Gabriel Holding A/S that GAB Invest ApS on 2 June 2020 has sold 50,000 shares in Gabriel Holding A/S corresponding to 2.65% of the share capital and voting rights in Gabriel Holding A/S.Following the sale of shares in Gabriel Holding A/S, GAB Invest ApS now holds 141,239 shares corresponding to 7.47% of the share capital and voting rights in Gabriel Holding A/S.AttachmentGabriel Holding AS – Announcement no 8 – Major holdings

Med henvisning til Kapitalmarkedslovens § 30 oplyses det hermed, at GAB Invest ApS i henhold til Kapitalmarkedslovens § 38, stk. 1, har meddelt Gabriel Holding A/S, at GAB Invest ApS d. 2. juni 2020 har solgt 50.000 stk. aktier i Gabriel Holding A/S svarende til 2,65% af aktiekapitalen og stemmerne i Gabriel Holding A/S.Efter salget af aktierne i Gabriel Holding A/S, har GAB Invest ApS en beholdning på i alt 141.239 aktier, svarende til 7,47% af aktiekapitalen og stemmerne i Gabriel Holding A/S.Vedhæftet filGabriel Holding AS – Meddelelse nr. 8 – Storaktionær

In accordance with Article 19 of the Market Abuse Regulation, Gabriel Holding A/S publishes the following transaction.AttachmentGabriel Holding AS – Announcement no 7 – Managers Transaction

I henhold til Markedsmisbrugsforordningen art. 19 offentliggør Gabriel Holding A/S følgende transaktion.Vedhæftet filGabriel Holding AS – Meddelelse nr. 7 – transaktion ledende medarbejder

MONMOUTH JUNCTION, N.J., June 03, 2020 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the successful closing of its previously announced private placement of $16.0 million of common stock at a price of $1.00 per share (representing a 34% premium at signing) to Syntone Ventures LLC, a U.S.-based affiliate of Syntone Technologies Group Co. Ltd.Outlook Therapeutics intends to use the net proceeds from the financing for working capital and general corporate purposes, including in support of its development program for ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab to treat wet AMD,...

CHESTERBROOK, Pa., June 03, 2020 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the Company’s partner in China has been approved by the Chinese National Medical Products Administration (NMPA) to initiate clinical trials for IV oliceridine, Trevena’s lead investigational asset for the management of moderate-to-severe acute pain. Jiangsu Nhwa holds an exclusive license agreement for the development and commercialization of oliceridine in China.“I am pleased to have reached this important regulatory milestone for IV oliceridine ,” said Carrie Bourdow, President and Chief Executive Officer of Trevena, Inc. “As we work towards our August 7th PDUFA date for potential...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, June 03, 2020 (GLOBE NEWSWIRE) — Luminex Resources Corp. (TSXV: LR) (the “Company” or “Luminex”) is pleased to announce that it has entered into an agreement with a syndicate of agents, led by Haywood Securities Inc. (collectively, the “Agents”), that have agreed to sell, on a commercially reasonable efforts private placement basis, up to 9,286,000 common shares (“Shares”) at a price of C$0.70 per Share (the “Offering Price”), for aggregate gross proceeds of up to C$6,500,200 (the “Brokered Offering”). In addition, the Company intends to complete a concurrent non-brokered private placement of up to C$3,500,000 worth of Shares (the “Non-Brokered Offering”, and together with the Brokered Offering, the “Offering”),...